Control of Mitochondrial Energy Production in Vivo

  • D. J. Taylor

Abstract

The study of purified enzymes and isolated mitochondria under well-defined conditions has provided a wealth of information about cellular metabolism over the past 50 years. However, results from studies on these reconstructed systems define the possible range of activity rather than the actual activity in vivo. In intact tissue the metabolic networks which we divide artificially into “glycolysis” and “oxidative phosphorylation” work as a unit, responding in concert to stimuli and effectors which are constantly in flux. The relationship of the properties of macromolecules and organelles to tissue metabolism can ultimately be understood only through non-invasive studies in vivo. 31 Phosphorus nuclear magnetic resonance (31P MRS) allows continuous measurement of the major phosphorus-containing metabolites and intracellular pH (pHi) in many tissues (Radda & Taylor, 1985; Radda et al., 1988). These metabolites are ATP, phosphocreatine (PCr), Pi, phosphodiesters (PDE) and phosphomonoesters (PME). The information on all of these variables is gathered simultaneously and without affecting the processes being investigated. This technique provides an excellent means of investigating the integration of mitochondrial activity into the overall energy metabolism of muscle. The approach in our laboratory has been to study the control and coordination of these pathways in normal and diseased human by observing with MRS the biochemical response to stress. Exercise provides an energetic demand that can be varied by intensity and duration; glycolytic, glycogenolytic and oxidative defects impose other specific metabolic stresses on cellular energetics.

Keywords

Fatigue Lactate Rubber Pyruvate Fructose 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Argov Z, Bank WJ, Maris J, Leigh JS, Chance B. (1987) Muscle energy metabolism in human phosphofructokinase deficiency as recorded by 31P nuclear magnetic resonance spectroscopy. Ann Neurol 22:46–51PubMedCrossRefGoogle Scholar
  2. Arnold DL, Matthews PM, Radda GK (1984) Metabolic recovery after exercise and the assessment of mitochondrial function in human skeletal muscle by means of 31P NMR. Mag Res Med 1:307–315CrossRefGoogle Scholar
  3. Arnold DL, Taylor DJ, Radda GK (1985) Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol 18:189–196PubMedCrossRefGoogle Scholar
  4. Brosnan MJ, Taylor DJ, Walton J, Radda GK (1987) A study of muscle metabolism in a rare muscle disorder. In: Abstracts of the 6th Annual Meeting, Soc Mag Res Med, New York, p 589Google Scholar
  5. Edwards RHT, Dawson MJ, Wilkie DR, Gordon RE, Shaw D (1982) Clinical use of nuclear magnetic resonance in the investigation of myopathy. Lancet i:725–731CrossRefGoogle Scholar
  6. Edwards RHT, Griffiths RD, Radda GK, Taylor DJ (1985) Physiological and metabolic consequences of a defect in mitochondrial pyruvate oxidation. In: Abstracts of the 4th Annual Meeting, Soc Mag Res Med, London, pp 1221–1222Google Scholar
  7. Gadian DG, Radda GK, Ross BD, Hockaday J, Bore P, Taylor D, Styles P (1981) Examination of a myopathy by phosphorus nuclear magnetic resonance. Lancet ii:774–775CrossRefGoogle Scholar
  8. Hands LJ, Bore PJ, Galloway G, Morris PJ, Radda GK (1986) Muscle metabolism in patients with peripheral vascular disease investigated by 31P nuclear magnetic resonance spectroscopy. Clin Sci 71:283–290PubMedGoogle Scholar
  9. Hayes DJ, Hilton-Jones D, Arnold DL, Galloway G, Styles P, Duncan J, Radda GK (1985) A mitochondrial encephalomyopathy: A combined 31P magnetic resonance and biochemical investigation. J Neuro Sci 71:105–118CrossRefGoogle Scholar
  10. Hayes DJ, Taylor DJ, Bore PJ, Hilton-Jones D, Arnold DL, Squire MV, Gent AE, Radda GK (1987) An unusual metabolic myopathy: a malate-aspartate shuttle defect. J Neuro Sci 82:27–39CrossRefGoogle Scholar
  11. Radda GK (1986) The use of NMR spectroscopy for the understanding of disease. Science 233:640–645PubMedCrossRefGoogle Scholar
  12. Radda GK, Bore PJ, Gadian DG, Ross BD, Styles P, Taylor DJ, Morgan-Hughes JA (1982) 31P NMR examination of two patients with NADH-CoQ reductase deficiency. Nature (London) 295:608–609CrossRefGoogle Scholar
  13. Radda GK, Bore PJ, Rajagopalan B (1984) Clinical aspects of 31P NMR spectroscopy. Brit Med Bull 40:155–159PubMedGoogle Scholar
  14. Radda GK, Rajagopalan B, Taylor DJ (1988) Biochemistry in vivo: An appraisal of clinical magnetic resonance spectroscopy. Magnetic Resonance Annual. Raven Press, New York (in press)Google Scholar
  15. Radda GK, Taylor DJ (1985) Applications of nuclear magnetic resonance spectroscopy in pathology. In: Richter GW, Epstein MA (eds) International Review of Experimental Pathology. Academic Press, New York London, pp 1–58Google Scholar
  16. Ross BD, Radda GK, Gadian DG, Rocker G, Esiri M, Falconer-Smith J (1981) Examination of a case of suspected McArdle’s syndrom by 31P NMR. New Eng J Med 304:1338–1342PubMedCrossRefGoogle Scholar
  17. Taylor J, Bore PJ, Styles P, Gadian DG, Radda GK (1983) Bioenergetics of intact human muscle — a 31P nuclear magnetic resonance study. Mol Biol Med 1:77–94PubMedGoogle Scholar
  18. Taylor DJ, Styles P, Matthews PM, Arnold DL, Gadian DG, Bore PJ, Radda GK (1986) Energetics of human muscle: Exercise-induced ATP depletion. Mag Res Med 3:44–54CrossRefGoogle Scholar
  19. Veech RL, Lawson JRW, Cornel NW, Krebs HA (1979) Cytosolic phosphorylation potential. J Biol Chem 254:6538–6547PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • D. J. Taylor
    • 1
  1. 1.MRC Biochemical and Clinical Magnetic Resonance UnitUniversity of Oxford, John Radcliffe HospitalOxfordEngland

Personalised recommendations